Ragoonanan, DristhiKhazal, Sajad J.Abdel-Azim, HishamMcCall, DavidCuglievan, BrankoTambaro, Francesco PaoloAhmad, Ali HaiderRowan, Courtney M.Gutierrez, CristinaSchadler, KeriLi, ShulinDi Nardo, MatteoChi, LindaGulbis, Alison M.Shoberu, BasiratMireles, Maria E.McArthur, JenniferKapoor, NeenaMiller, JeffreyFitzgerald, Julie C.Tewari, PritiPetropoulos, DemetriosGill, Jonathan B.Duncan, Christine N.Lehmann, Leslie E.Hingorani, SangeetaAngelo, Joseph R.Swinford, Rita D.Steiner, Marie E.Hernandez Tejada, Fiorela N.Martin, Paul L.Auletta, JefferyWon Choi, SungBajwa, RajinderDailey Garnes, NatalieKebriaei, PartowRezvani, KatayounWierda, William G.Neelapu, Sattva S.Shpall, Elizabeth J.Corbacioglu, SelimMahadeo, Kris M.2025-03-112025-03-112021Ragoonanan D, Khazal SJ, Abdel-Azim H, et al. Author Correction: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2021;18(7):468. doi:10.1038/s41571-021-00497-xhttps://hdl.handle.net/1805/46285Correction to: Nature Reviews Clinical Oncology https://doi.org/10.1038/s41571-021-00474-4, published online 19 February 2021. In the original version of this Consensus Statement, the name of the author Christine N. Duncan was incorrectly written as Christine N. Duncun. In addition, Fig. 1 contained errors regarding the criteria to grade cytokine-release syndrome (CRS). “Hypotension not requiring vasopressors” has now been corrected to “hypotension requiring one vasopressor ± vasopressin” for grade 3 CRS and “hypotension requiring multiple vasopressors, not including vasopressin” for grade 4 CRS. The affiliations and Fig. 1 have been corrected in the HTML and PDF versions of the manuscript.en-USAttribution 4.0 InternationalDrug-related side effects and adverse reactionsNeoplasmsImmunotherapyTransfusion reactionArticle